Corynebacterium diphtheriae

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Corynebacterium diphtheriae
Accession Number
DB09877
Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Other vaccines
Description

Corynebacterium diphtheriae toxin is extracted from the pathogenic actinobacterium C. diphtheriae that causes diphtheria. The bacteria culture is grown in a medium and through purification, diphtheria toxin is detoxified with formaldehyde and diafiltered. The vaccine is intramuscularly administered to provide active immunization against diphtheria in infants and children.

Synonyms
Not Available
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Prevnar 13Corynebacterium diphtheriae (34 mcg/0.5mL) + Streptococcus pneumoniae type 1 capsular polysaccharide antigen (2.2 mcg/0.5mL) + Streptococcus pneumoniae type 14 capsular polysaccharide antigen (2.2 mcg/0.5mL) + Streptococcus pneumoniae type 18c capsular polysaccharide antigen (2.2 mcg/0.5mL) + Streptococcus pneumoniae type 19a capsular polysaccharide antigen (2.2 mcg/0.5mL) + Streptococcus pneumoniae type 19f capsular polysaccharide antigen (2.2 mcg/0.5mL) + Streptococcus pneumoniae type 23f capsular polysaccharide antigen (2.2 mcg/0.5mL) + Streptococcus pneumoniae type 3 capsular polysaccharide antigen (2.2 mcg/0.5mL) + Streptococcus pneumoniae type 4 capsular polysaccharide antigen (2.2 mcg/0.5mL) + Streptococcus pneumoniae type 5 capsular polysaccharide antigen (2.2 mcg/0.5mL) + Streptococcus pneumoniae type 6a capsular polysaccharide diphtheria crm197 protein conjugate antigen (2.2 mcg/0.5mL) + Streptococcus pneumoniae type 6b capsular polysaccharide antigen (4.4 mcg/0.5mL) + Streptococcus pneumoniae type 7f capsular polysaccharide antigen (2.2 mcg/0.5mL) + Streptococcus pneumoniae type 9v capsular polysaccharide antigen (2.2 mcg/0.5mL)SuspensionIntramuscularPfizer2010-03-01Not applicableCanada
Tetanus and Diphtheria Toxoids AdsorbedCorynebacterium diphtheriae (2.0 1/0.5mL) + Clostridium tetani (2.0 1/0.5mL)InjectionIntramuscularRebel Distributors1967-10-13Not applicableUs
Categories
Not Available
UNII
3U7E3O07S8
CAS number
Not Available

Pharmacology

Indication
Not Available
Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347910466
Wikipedia
Corynebacterium_diphtheriae

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentStage III Hepatocellular Carcinoma AJCC v8 / Stage III Intrahepatic Cholangiocarcinoma AJCC v8 / Stage IIIA Hepatocellular Carcinoma AJCC v8 / Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 / Stage IIIB Hepatocellular Carcinoma AJCC v8 / Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 / Stage IV Hepatocellular Carcinoma AJCC v8 / Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 / Stage IVA Hepatocellular Carcinoma AJCC v8 / Stage IVB Hepatocellular Carcinoma AJCC v8 / Unresectable Hepatocellular Carcinoma / Unresectable Intrahepatic Cholangiocarcinoma1
1CompletedPreventionInfections, Pneumococcal1
1, 2CompletedPreventionInfections, Pneumococcal / Infections, Streptococcus Pneumoniae1
1, 2RecruitingOtherHealthy Volunteers1
1, 2RecruitingPreventionHealthy Volunteers / Pneumococcal Diseases1
2CompletedPreventionInfections, Pneumococcal3
3CompletedPreventionBacterial Infections / Neisseria Meningitidis / Virus Diseases1
3CompletedPreventionMumps / Rubella / Rubeola1
3Not Yet RecruitingPreventionInfections, Pneumococcal1
3RecruitingPreventionInfections, Pneumococcal4
3RecruitingPreventionInfections, Pneumococcal / Vaccines, Pneumococcal1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SuspensionIntramuscular
InjectionIntramuscular
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on November 30, 2015 14:23 / Updated on June 04, 2019 07:13